Implementation and Assessment of a Medication Therapy Management Program in HIV Patients at High Risk of Adverse Drug Events at Khartoum, Sudan

Completed · Not applicable

Conditions studied: HIV Infections

In brief

This clinical trial aims to evaluate the effectiveness and cost-effectiveness of two levels of a pharmacist-led Medication Therapy Management (MTM) program, Basic MTM and Enhanced MTM, compared with usual care for HIV patients at high risk of adverse drug events in Khartoum, Sudan. The primary objective is to determine whether Basic MTM or Enhanced MTM improves medication adherence, measured by the Proportion of Days Covered (PDC ≥95%) at the primary 6-month assessment, with follow-up continuing for 24 months. Secondary objectives include evaluating the effects of the interventions on viral load suppression, CD4+ cell count, adverse drug events, drug-related problems, health-related quality of life, patient satisfaction, treatment self-efficacy, and cost-effectiveness. Participants will be randomly assigned in a 1:1:1 ratio to one of three study groups: Arm 1: Usual Care Arm 2: Basic Medication Therapy Management (Basic MTM) Arm 3: Enhanced Medication Therapy Management (Enhanced MTM) All participants will attend study visits at baseline and at 6, 12, 18, and 24 months to complete study questionnaires and undergo routine clinical assessments, including viral load and CD4+ measurements. Participants assigned to the Basic MTM group will receive usual care plus structured pharmacist-led Medication Therapy Management, including comprehensive medication reviews, a personal medication record, a medication action plan, five face-to-face MTM visits (baseline and every six months thereafter), and four scheduled telephone follow-up calls over the 24-month study period. Participants assigned to the Enhanced MTM group will receive all components of Basic MTM together with more frequent face-to-face visits, monthly during the first three months and every three months thereafter, additional telephone support for high-risk participants, adherence support tools (such as pill organizers and medication reminder tools), enhanced communication with prescribers, and home visits when appropriate. Do these MTM interventions improve clinical outcomes, such as viral load suppression and CD4+ cell count, compared to usual care? Researchers will compare three groups (Arm 1: Usual Care; Arm 2: Basic MTM; Arm 3: Enhanced MTM) to determine whether the MTM interventions lead to better medication adherence, fewer adverse drug events, improved quality of life, and greater cost-effectiveness. Participants will: Be randomly assigned to one of three groups: Usual Care, Basic MTM, or Enhanced MTM. Attend scheduled research assessment visits at baseline, 6, 12, 18, and 24 months to complete questionnaires (on adherence, quality of life, etc.) and provide blood samples for routine lab tests (viral load, CD4 count). If assigned to Basic MTM: Participate in 4 face-to-face sessions and 4 telephone follow-ups with a trained pharmacist over 24 months for medication reviews, education, and adherence support. If assigned to Enhanced MTM: Participate in 8 face-to-face sessions and 8 telephone follow-ups with a trained pharmacist over 24 months, and receive enhanced support tools (e.g., pillboxes, alarm devices) and potentially home visits.

Key facts

Study ID

NCT07750834

Run by

Universiti Sains Malaysia

People needed

1149

Starts

2021-01-01

Expected to finish

2026-04-01

Last updated by the study team

2026-08-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: ≥18 years at the time of enrollment.
• HIV Status: Laboratory-confirmed HIV infection.
• ART Duration: Receiving antiretroviral therapy (ART) for at least 3 months prior to enrollment.
• -Language and Consent: Able to communicate in Arabic or English and willing and able to provide written informed consent.
• High-Risk Status: Meeting at least 2 of the following high-risk criteria:
• Receiving ≥8 chronic medications, including ART and medications for comorbidities.
• Having ≥3 chronic comorbidities (e.g., diabetes mellitus, hypertension, hepatitis, or tuberculosis).
• Documented or self-reported adverse drug event within the previous 12 months.
• Viral load >200 copies/mL during the previous 6 months.
• -Self-reported medication adherence <95% or repeated missed clinic appointments.
• Attendance at the participating HIV clinic on at least 2 occasions during the assessment period.

You may not qualify if…

• Age <18 years.
• Pregnancy.
• Significant cognitive impairment preventing informed consent or study participation.
• Terminal illness with expected life expectancy <12 months.
• Concurrent participation in another pharmacological intervention study.
• Previous participation in a formal Medication Therapy Management (MTM) program within the past year.
• Planned relocation away from Khartoum State during the follow-up period.
• Inability to provide informed consent for any reason.

Where it is running

• Omdurman teaching Hospital — Khartoum, Omdurman, Sudan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.